Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
PRQR Stock Chart & Stats
$2.14
-$0.10(-3.77%)
At close: 4:00 PM EST
$2.14
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.07 - $3.27
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$238.83M
Enterprise Value$91.96M
Total Cash (Recent Filing)$106.88M
Total Debt (Recent Filing)$16.49M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Feb 19, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding105,212,524
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio2.63
Price to Book (P/B)2.36
Price to Sales (P/S)11.05
P/FCF Ratio-5.53
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit5.91
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$7.25Price Target Upside238.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ValuationProQR is seen as significantly undervalued compared to other RNA editing peers, especially given its wholly owned pipeline and active clinical program with AX-0810.
Platform ValidationAX-0810's Phase 1 readout has the potential to validate ProQR’s Axiomer platform in humans and open expansion opportunities into broader fibrotic and metabolic diseases.
Strategic PartnershipsThe partnership with Eli Lilly provides external validation for ProQR, enhancing its credibility and potential in the market.
Bears Say
Durability ConcernsThere is a need for long-term monitoring to provide confidence in the durability of editing and to rule out potential immune activation.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.07 and its highest was $3.27 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $238.83M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Feb 19, 2026 which is in 62 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Nov 06, 2025. The company reported -$0.117 earnings per share for the quarter, beating the consensus estimate of -$0.118 by $0.001.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.12.
How many shares outstanding does ProQR have?
ProQR has 105,212,524 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.117 in its last earnings report, beating expectations of -$0.118. Following the earnings report the stock price went down -7.143%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (238.79% Upside)
$7.25 (238.79% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-99.45%
Trailing 12-Months
Asset Growth
27.61%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V. is a biotechnology company focused on developing transformative RNA therapies for genetic diseases. Founded in 2012 and headquartered in Leiden, Netherlands, ProQR operates primarily in the biopharmaceutical sector, specializing in innovative solutions for rare genetic disorders, including eye diseases and other severe conditions. The company's core products include RNA-based therapeutics designed to address the underlying causes of genetic mutations, leveraging its proprietary platform for RNA repair and replacement.
PRQR Stock 12 Month Forecast
Average Price Target
$7.25
▲(238.79% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.78% Mutual Funds
26.03% Other Institutional Investors
71.82% Public Companies and
Individual Investors